QSI stock extends slide as Quantum-Si focuses on cash and diagnostics platform

Published on 09/04/2026 at 13:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

QSI stock continues to trade deep below its 52-week high while Quantum-Si works to commercialize its protein sequencing platform and manage cash burn ahead of upcoming earnings.

QSI, US7491641091, Illustration mit AI erstellt.

Quantum-Si Incorporated (ISIN US7491641091) stock (ticker QSI) remains under pressure, with the shares trading far below their 52-week high as of September 4, 2026 according to data from a German stock portal.

QSI stock trades near the bottom of its range

As of September 4, 2026, one German market overview shows QSI at a realtime price of 0.76 USD, reflecting a gain of 0.36 percent over the previous 24 hours and a seven-day performance of minus 11.11 percent.

The same overview indicates that QSI is currently 75.44 percent below its 52-week high and 9.92 percent above its 52-week low, underscoring how far the stock has fallen over the past year and how closely it is still trading to the bottom of its range.

Recent fundamentals frame the risk-reward

According to recent financial portal data for the latest reported year, Quantum-Si generated a full-year revenue figure in the tens of millions of USD and continued to post a net loss, highlighting the typical profile of a pre-profit diagnostics technology company; these figures refer to the most recently reported fiscal year, which falls within the last 24 months and therefore still frame the current business picture.

The same set of results shows that operating expenses remained high relative to revenue, leading to a negative operating margin in the latest year and underscoring that QSI stock is still largely driven by expectations about future adoption of its platform rather than current profitability.

For investors, the combination of a share price that is 75.44 percent below the 52-week high and an early-stage fundamental profile means that any change in guidance or adoption metrics in the next quarterly report could have an outsized impact on the valuation.

Go deeper

More on QSI stock and filings

Background information on Quantum-Si and regulatory filings can be found via the AD HOC NEWS topic page and the company's investor relations site.

All news on QSI stock Investor Relations

Diagnostics platform and product focus

Quantum-Si is positioning its protein sequencing and diagnostics platform as a complement to established genomic tools, targeting applications in research labs and clinical diagnostics where higher-resolution insights into the proteome can improve disease understanding and treatment decisions.

The company's core product offering combines a benchtop instrument with consumables and cloud-based analytics, creating a recurring revenue model once installed instruments begin to drive regular chip and reagent demand.

Stock remains speculative at current levels

With QSI trading at 0.76 USD as of September 4, 2026 on its primary listing in the United States, the stock price continues to reflect both the substantial downside from the 52-week high and the potential upside if Quantum-Si manages to translate its technology into growing and profitable revenue streams.